BridgeBio Pharma (BBIO) vs Corcept Therapeutics (CORT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Corcept Therapeutics (CORT) has outperformed BridgeBio Pharma (BBIO) over the past year, gaining 32.4% versus a gain of 22.6%. Over five years, CORT leads with a +496.8% price change compared with +38.6% for BBIO. BridgeBio Pharma is the larger company by market cap ($13.00 billion vs $12.93 billion), about 1.0 times the size.
On valuation, Corcept Therapeutics trades at a lower forward P/E (27.2x vs 2420.8x for BridgeBio Pharma). Corcept Therapeutics converts more of its revenue into profit, with a net margin of 13.1% versus -146.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBIO | CORT |
|---|---|---|
| Share price | $66.50 | $119.60 |
| Market cap | $13.00B | $12.93B |
| 1-day change | -0.69% | +0.03% |
| YTD return | -13.06% | +243.68% |
| 1-year return | +22.65% | +32.42% |
| 5-year return | +38.60% | +496.81% |
| P/E ratio (TTM) | — | 265.78 |
| Forward P/E | — | 27.17 |
| EPS (TTM) | $-3.56 | $0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $502.08M | $761.41M |
| Revenue growth (YoY) | +126.26% | +12.79% |
| Net income (latest FY) | $-732.94M | $99.65M |
| Gross margin | 95.82% | 98.30% |
| Operating margin | -104.25% | 5.88% |
| Net margin | -145.98% | 13.09% |
| 52-week high | $93.42 | $126.38 |
| 52-week low | $52.75 | $28.66 |
| Distance from 52-week high | -28.81% | -5.36% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +63.98% | +17.89% |
| Average volume | 2.76M | 1.31M |
| Shares outstanding | 195.49M | 108.10M |
| Employees | 999 | 730 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Corcept Therapeutics is more profitable, keeping 13.1 cents of every revenue dollar as net income versus -146.0 cents for BridgeBio Pharma.
- BridgeBio Pharma grew revenue faster in its latest fiscal year (+126.26% vs +12.79%).
About BridgeBio Pharma
BBIO stock →BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Health Care · Biotechnology: Pharmaceutical Preparations · 999 employees
About Corcept Therapeutics
CORT stock →Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Health Care · Biotechnology: Pharmaceutical Preparations · 730 employees
BBIO vs CORT FAQ
Which is bigger, BridgeBio Pharma or Corcept Therapeutics?
BridgeBio Pharma (BBIO) is larger, with a market capitalization of $13.00B compared with $12.93B for Corcept Therapeutics (CORT).
Which stock has performed better over the past year, BBIO or CORT?
CORT returned +32.42% over the past 12 months, compared with +22.65% for BBIO (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Pharma and Corcept Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.